A new review published online in the Journal of Intensive Medicine on July 6, 2026, led by a team including researchers at Mayo Clinic in Arizona, with collaborators at the University of Pennsylvania in the United States and Mansoura University in Egypt, assembles the current evidence on sepsis-associated atrial fibrillation, abbreviated SAAF. The review examines how often the arrhythmia occurs, which patients are most vulnerable, how it is detected and diagnosed, and how it is currently managed, before laying out the research agenda needed to close the remaining gaps. The corresponding author, Sameh Hozayen, MB, BCh, of the Division of Hospital Internal Medicine at Mayo Clinic in Arizona, describes the condition as sitting in a clinical blind spot: common, dangerous, and treated without a map. The stated aim of the review is to bring existing evidence together in one place and to define precisely what still needs to be learned so that these patients can receive standardized, evidence-based care rather than ad hoc, institution-by-institution improvisation.

The clinical stakes are considerable. Unlike primary atrial fibrillation, which arises without a clear acute trigger and is supported by decades of randomized trial data and established treatment guidelines, SAAF develops in response to the acute stress of critical illness. In many patients it resolves once the underlying infection is brought under control, which has historically encouraged the assumption that it is a transient and relatively benign companion to sepsis. The review makes clear that this assumption is untenable. Sepsis-associated atrial fibrillation is associated with a 4.6-fold increase in stroke risk and a 1.7-fold increase in in-hospital mortality compared with sepsis patients who never develop the arrhythmia. Recurrence is common, affecting up to half of patients within five years, and survivors carry elevated risks of heart failure, stroke, and death that persist long after they have been discharged from the hospital and the acute infection has been cured.

Part of what makes SAAF so difficult to manage is that its causes are fundamentally multifactorial. The review traces a convergence of mechanisms: systemic inflammation driven by the septic response, autonomic dysfunction that disrupts the neural regulation of heart rate, direct myocardial injury, hemodynamic stress from fluctuating blood pressure and fluid shifts, and electrolyte disturbances that destabilize the electrical properties of the atria. Each of these forces alone can promote arrhythmia; together, in a critically ill patient, they create an environment in which the heart’s upper chambers are pushed toward disorganized electrical activity. This mechanistic complexity also explains why the arrhythmia’s course tracks so closely with the trajectory of the underlying illness, waxing and waning as the infection, the inflammatory response, and the patient’s hemodynamic status evolve hour by hour.

That volatility would be challenging enough on its own, but the therapeutic landscape is complicated by a more fundamental problem: no randomized studies have compared management strategies specifically in this population. Clinicians are therefore forced to extrapolate from trials conducted in patients with primary atrial fibrillation, an imperfect fit for critically ill patients whose physiology can shift dramatically within hours and whose organ dysfunction alters drug metabolism, tolerance, and risk. The review is explicit that this extrapolation, while unavoidable in current practice, leaves every major treatment decision shadowed by uncertainty, and that acknowledging that uncertainty is the first step toward designing the studies that will eventually resolve it.

The uncertainties begin with the simplest question: how fast should the heart be allowed to beat? For rate control, beta-blockers appear superior to alternative agents in observational data, but no randomized trial has confirmed which approach is genuinely best in septic patients, who may tolerate beta-blockade poorly when blood pressure is fragile. For rhythm control, electrical cardioversion can restore normal sinus rhythm, yet it frequently fails to hold while the underlying illness persists, because the same inflammatory, autonomic, and metabolic forces that triggered the arrhythmia remain active and quickly reassert themselves. Choosing between accepting a rapid rhythm and repeatedly attempting to restore sinus rhythm is, at present, a matter of clinical judgment rather than evidence.

The thorniest question of all is anticoagulation, the use of blood-thinning medication to prevent the clots that cause stroke in atrial fibrillation. Critically ill patients with sepsis face simultaneous and opposing risks: dangerous clotting on one side and dangerous bleeding on the other. Standard stroke-risk prediction tools used to guide anticoagulation in primary atrial fibrillation have not been validated in the sepsis setting, so the usual calculus for deciding who should be treated does not reliably apply. In observational studies, anticoagulation has not clearly reduced stroke risk in these patients—and in one multicenter cohort it actually increased bleeding—leading many clinicians to defer it. The review stresses that deferral or initiation must be individualized to each patient’s phase of illness, weighing the evolving clotting and bleeding risks as sepsis progresses or resolves, rather than applying a fixed rule.

Against this backdrop of uncertainty, the review distills the field’s needs into concrete research priorities. The authors call for a universally accepted definition of sepsis-associated atrial fibrillation, without which studies cannot be compared or pooled; validated prediction models to identify high-risk patients early in their illness; prospective randomized trials comparing rate control and rhythm control strategies; clearer, evidence-based anticoagulation strategies tailored to the phases of sepsis; and standardized rhythm monitoring after discharge to capture recurrence and long-term outcomes that are currently invisible to follow-up care. The authors also underscore the economic dimension of the problem: SAAF adds roughly 9,000 dollars in charges per patient, a substantial burden multiplied across the millions of sepsis admissions worldwide each year. Emerging technologies may help close the detection gap, and the review points to growing roles for artificial intelligence in predicting and detecting the arrhythmia in real time, potentially flagging high-risk patients before the rhythm deteriorates.

Until dedicated trials are completed and the research priorities are fulfilled, the authors conclude, the management of sepsis-associated atrial fibrillation will remain a matter of careful, individualized judgment. The central message for clinicians is to treat the whole critically ill patient rather than the arrhythmia in isolation: controlling the infection, correcting electrolyte disturbances, supporting hemodynamics, and reassessing rhythm and anticoagulation decisions continuously as the patient’s condition changes. For researchers, the message is equally direct. A condition that affects as many as one in five sepsis patients, multiplies stroke risk nearly fivefold, and drives measurable excess mortality and cost can no longer be managed on borrowed evidence from a different disease. The review’s roadmap—definition, prediction, randomized comparison of treatments, rational anticoagulation, and structured follow-up—offers the first coordinated plan for turning a clinical blind spot into standardized, evidence-based care.

Subject of Research: Sepsis-associated atrial fibrillation: incidence, risks, diagnosis, and management

Article Title: Atrial fibrillation during sepsis: what clinicians know—and what remains unclear

Article References: Atrial fibrillation during sepsis: what clinicians know—and what remains unclear. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: atrial fibrillation, sepsis, critical care, stroke risk, anticoagulation, rate control, rhythm control, intensive care medicine, arrhythmia, clinical review, artificial intelligence, research priorities

The trial enrolled 262 patients with symptomatic paroxysmal or persistent atrial fibrillation and randomised them in a 2:1 ratio to pulmonary vein isolation or to a sham procedure. The primary endpoint was the between-group difference in the change from baseline to six months in the AFEQT summary score, a well-established questionnaire measuring atrial fibrillation-related quality of life. At six months, the mean AFEQT score improved from 61 to 81 in the ablation group and from 59 to 75 in the sham group. Both improvements were clinically meaningful, but the difference in change between the groups was not statistically significant. Meanwhile, ablation demonstrated clear objective efficacy: atrial fibrillation was detected in 21 percent of ablated patients versus 41 percent of sham patients, an absolute difference of 20 percent, with a favourable safety profile.

What distinguishes PVI-SHAM-AF from earlier research is the rigor of its control condition. The sham intervention was not an inert experience but an active clinical pathway encompassing hospital admission, deep sedation and analgesia, venous access, a stay in the catheterization laboratory, cardioversion for patients who arrived in atrial fibrillation, and structured follow-up. The trial therefore tested catheter ablation against this comprehensive procedural and clinical-care package, not against no treatment at all. The investigators emphasise that the study did not evaluate conventional non-invasive ambulatory care. Within the six-month observation window, however, the superior rhythm control achieved by ablation simply did not translate into a statistically significant improvement in patient-reported quality of life beyond what the active sham pathway delivered.

Compared with the two previous sham-controlled ablation trials, SHAM-PVI and PFA-SHAM, PVI-SHAM-AF was substantially larger, exceeding the combined sample size of both predecessors. Baseline quality of life was impaired to a similar degree as in the major open-label trials CABANA and EARLY-AF. Intriguingly, while the improvement within the ablation arms was broadly consistent across all these studies, the improvement observed in the sham arm of PVI-SHAM-AF was markedly lower than in SHAM-PVI and PFA-SHAM. The editorial authors suggest this discrepancy indicates that patient management in PVI-SHAM-AF may have been more comprehensive than in the other two sham trials, intensifying the care received by the control group and thereby narrowing the apparent treatment effect on symptoms.

The findings echo a broader pattern in cardiovascular medicine. Previous reports have documented clinically relevant placebo effects in randomised trials of invasive procedures across settings as varied as resistant hypertension, percutaneous coronary intervention and vertebroplasty for osteoporotic vertebral fractures. A systematic review and meta-analysis found that only about a third of placebo-controlled trials of cardiovascular interventions demonstrated significant superiority of the invasive procedure over placebo. Against this backdrop, PVI-SHAM-AF is less an outlier than a striking confirmation that subjective, patient-reported endpoints are acutely susceptible to contextual healing, expectation and the attention that accompanies any hospital-based intervention.

Why did both groups improve so substantially? The editorial points to a likely combination of placebo and Hawthorne effects, regression to the mean, and optimised concomitant care driven by protocol-adherent assessments and intensive follow-up. Symptoms in atrial fibrillation, the authors argue, may not be determined solely by arrhythmia physiology but also by symptom perception, atrial or ventricular ectopy, anxiety and depression. Quantifying the individual contributions of these mechanisms is difficult, and PVI-SHAM-AF was not designed to isolate them. Disentangling how much of the improvement stems from the procedure itself, from heightened clinical attention, or from psychological factors remains a critical objective for future research and could reshape how symptom-directed therapies are evaluated.

Do the results mean ablation fails to relieve symptoms, or that it should be withheld from patients with preserved left ventricular function? The editorial authors firmly reject both conclusions. The trial demonstrates that ablation reduces atrial fibrillation recurrence and burden safely, and it does not challenge indications in settings where reducing arrhythmia burden may improve clinically relevant outcomes, such as tachycardia-induced or atrial fibrillation-aggravated cardiomyopathy and heart failure with reduced ejection fraction, populations that were not the focus of this study. The results are confined to patient-reported outcomes rather than morbidity or mortality, reflecting a familiar divergence in cardiology where effects on hard endpoints and on how patients feel can part ways, as seen with beta-blockers, inotropes and implantable cardioverter-defibrillators in heart failure.

Questions about patient selection and follow-up duration also deserve scrutiny. Data on the 937 patients who declined randomisation were insufficient for comparison, and willingness to accept an invasive sham procedure may have selected individuals with particular symptom burdens, expectations or treatment preferences; patients with severe symptoms might have declined to guarantee receiving ablation. Yet the mean baseline AFEQT score of 60 mirrored those in CABANA, EARLY-AF and STOP AF First, beta-blocker use remained high and balanced between groups, and no treatment effect heterogeneity by baseline score was observed. The six-month primary endpoint was chosen deliberately to minimise the impact of repeat procedures, but the authors concede it may have been too short to capture the full treatment effect, and it does not exclude longer-term benefits in rhythm control, medication use, healthcare utilisation or clinical outcomes. Twelve-month follow-up is ongoing.

For clinical practice, the implications centre on shared decision-making. PVI-SHAM-AF shows that the objective rhythm-control benefits of catheter ablation should be clearly distinguished from its effects on patient-reported quality of life at six months, information that is essential for counselling patients whose primary goal is symptom relief. The results also underscore the therapeutic power of comprehensive, attentive clinical care. Crucially, the authors stress that invasive sham procedures are research tools for delineating true treatment effects and must never be translated into clinical practice. Instead, the challenge is to identify which components of the sham-associated care pathway improved symptoms and how those elements can be incorporated into routine, non-invasive care.

Perhaps the trial’s most enduring lesson is methodological. The editorial demonstrates that randomised, blinded evaluation of an established, guideline-recommended invasive procedure is accepted by patients, accepted by many expert physicians, and feasible across multiple centres and countries. Sham-controlled designs are particularly important when evaluating subjective or patient-reported outcomes, because such endpoints are vulnerable to placebo effects, expectations, regression to the mean and the effects of intensified clinical care. Just as placebo controls are indispensable for drug therapies, the incremental effect of an invasive or surgical procedure on how patients feel cannot be reliably determined without an appropriate sham control. PVI-SHAM-AF may thus be remembered less for what it says about ablation alone and more for how it resets the standard of evidence for procedural medicine.

Subject of Research: A sham-controlled randomised trial evaluating catheter ablation for symptom relief and rhythm control in patients with symptomatic atrial fibrillation.

Article Title: PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?

Article References: Laufs, U., Böhm, M., Mahfoud, F., & Wachter, R. (2026). PVI-SHAM-AF: what does this trial tell us about catheter ablation and symptoms in patients with atrial fibrillation?. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03016-z

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03016-z

Keywords: atrial fibrillation, catheter ablation, pulmonary vein isolation, sham-controlled trial, quality of life, AFEQT score, placebo effect, rhythm control, patient-reported outcomes, PVI-SHAM-AF, cardiology, clinical trial